# Diabetic Kidney Disease: Layer Protection and Recheck the Diagnosis

Track kidney function, potassium, volume status, adverse effects, and patient priorities. An early physiological change may differ from progressive kidney injury.

![Infographic: Diabetic Kidney Disease: Layer Protection and Recheck the Diagnosis](https://urinenephrology.org/visual-reference/images/mastery-dkd.png?v=20261003c)

## Multiple injury pathways

Hyperglycemia, hemodynamic stress, inflammation, and vascular disease contribute to diabetic kidney disease. Albuminuria and filtration provide complementary risk information.

## Check for another disease

Abrupt decline, active sediment, unusual protein patterns, or discordant clinical features warrant reconsideration rather than automatic attribution to diabetes.

## Assess the whole risk profile

Review blood pressure, glycemia, albuminuria, cardiovascular disease, potassium, medication tolerance, and access to care.

## Layer by indication

For type 2 diabetes with CKD, an SGLT2 inhibitor is recommended when eGFR is ≥20 mL/min/1.73 m². Use ACEi/ARB for indicated albuminuric disease and consider finerenone for eligible patients with persistent albuminuria and acceptable potassium. A GLP-1 receptor agonist may address additional glycemic and cardiovascular needs.

## Keep metformin and organ protection distinct

Metformin eligibility changes as filtration declines: KDIGO recommends it for type 2 diabetes with eGFR ≥30 mL/min/1.73 m², with dose adjustment below 45. Stop below 30 and reassess during acute illness. An SGLT2 inhibitor may still offer organ benefit when its glucose-lowering effect is smaller.

## Schedule checks after each layer

Check BP, creatinine, and potassium within 2–4 weeks after starting or increasing ACEi/ARB. For finerenone, plan potassium reassessment at about 4 weeks. Review volume symptoms after SGLT2 initiation. Investigate substantial or progressive deterioration rather than treating every early eGFR dip as toxicity.

## Supporting evidence

- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)
- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf)

## Source lessons

- [dkd treatment](https://urinenephrology.org/mastery/ckd-advanced/dkd-treatment.html)
- [metformin ckd](https://urinenephrology.org/mastery/ckd-advanced/metformin-ckd.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.